Login to Your Account



Clinic Roundup


Friday, February 24, 2012
• Onyx Pharmaceuticals Inc., of South San Francisco, completed enrollment in the Phase III (ASPIRE) trial of carfilzomib in relapsed multiple myeloma. The trial will compare carfilzomib/lenolidomide/dexamethasone against lenolidomide and dexamethasone in 780 patients with relapsed multiple myeloma at about 200 sites, with a primary endpoint of progression-free survival and secondary endpoints including overall survival, overall response rate, duration of response, disease control rate, safety, time-to-progression and time-to-next-treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription